BRIEF-Sarepta Therapeutics announces EMA validation of Eteplirsen

* Sarepta Therapeutics announces EMA validation of

Eteplirsen authorization application for treatment of Duchenne

muscular Dystrophy amenable to exon skipping 51

Read more